Company profile
EVIO, Inc.
OTC: EVIO · Healthcare · Drug Manufacturers - Specialty & Generic
#731 of 1,422 Healthcare companies by revenue59th-percentile growth
EA Score
——FH —DQ 12GM —SS 50
v0.1 · 25/100 weight · pillars only
↑ 3-yr revenue growth, listing tenure · ↓ filing timeliness, Altman-Z
Methodology →Revenue TTM
$2.9M
Rev growth YoY (TTM)
-26.9%
Net income (FY)
-$18.5M
Employees
18
as of 2026-08-26
Market cap
$1.9M
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.8M$3.8M2019
Net income-$18.5M-$18.5M2019
Operating income-$7.3M-$7.3M2019
Total assets$8.4M$8.4M2019
Liabilities$20.2M$20.2M2019
Equity-$11.6M-$11.6M2019
Revenue trend
FY2016 – FY2019 · USD
FY16
FY17
FY18
FY19
FY19
Revenue by segment
Filed disclosures · FY2019
By product
Testing Revenue100%
Consulting Revenue0%
By geography
Not disclosed.
The read
What is EVIO, Inc.’s revenue?
EVIO, Inc. booked $3.8M in FY2019 revenue, growing 13% year over year — about the middle of the pack among Healthcare companies we track, at a -489.4% net margin.
Peers · Healthcare
Tenon Medical, Inc.35DNovaBridge Biosciences36DTarget Group Inc.46DCibus, Inc.43DNeurAxis, Inc.45DRed Light Holland Corp.——Neighbors
Clark →Key facts
CEOLori Jean Glauser
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersHenderson, NV
ExchangeOTC: EVIO
Employees18
IPO date2004-01-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.